Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines proposed the concept of acute kidney disease (AKD) to describe kidney dysfunction that does not meet the diagnostic criteria for either acute kidney injury (AKI) or chronic kidney disease (CKD). However, long-term prognosis, particularly with recovery after AKD, remains unclear. This study aimed to compare long-term outcomes among patients with recovery after AKD (Recovery group), those without recovery (Non-Recovery group), and those without AKD (non-AKD group).
This single-center retrospective cohort study included all adult patients without end-stage kidney disease (ESKD) who underwent at least one blood test at Hamamatsu University Hospital between January 1 and December 31, 2013. The median observation period was 112.9 months (interquartile range: 57.7–140.4 months). The first laboratory test performed in 2013 was defined as the index date. AKD was identified based on the KDIGO criteria using serum creatinine (S-Cre) and estimated glomerular filtration rate (eGFR) values within ±90 days of the index date. Recovery was evaluated at 6 months after the index date and was defined as meeting either of the following criteria: S-Cre ≤ 1.25 × baseline S-Cre or eGFR ≥ 0.8 × baseline eGFR. The primary outcome was all-cause mortality. The secondary outcome was the annual rate of eGFR decline (eGFR slope).
Of the 20,105 eligible patients, 14,459 met the inclusion criteria and were analyzed. The mean (SD) age was 61.2 (16.6) years, and 47.3% were men. The non-AKD, Recovery, and Non-Recovery groups comprised 13,830, 291, and 338 patients, respectively. Compared with the non-AKD group, both the Recovery group (hazard ratio [HR] 2.08, 95% confidence interval [CI] 1.57–2.74) and the Non-Recovery group (HR 2.03, 95% CI 1.50–2.73) showed significantly higher mortality risk, with no significant difference between the two AKD groups. The between-group differences in 1-year eGFR slope (mL/min/1.73 m²/year) versus the non-AKD group were −0.93 (95% CI, −3.34 to 1.47) the Recovery group and −1.84 (95% CI, −4.65 to 0.97) for the Non-Recovery group, with no significant differences.
After adjustment for age, sex, renin–angiotensin system inhibitor use, and comorbidities, the results remained consistent (Recovery: −0.75 [95% CI, −3.16 to 1.66], Non-Recovery: −0.92 [95% CI −3.77 to 1.93]).
The development of AKD was associated with an increased risk of all-cause mortality, regardless of recovery status. In contrast, the rate of kidney function decline did not differ significantly among the groups. These findings suggest that patients with AKD require careful long-term monitoring even after kidney function recovery.
